Home › Research › Risk factors
Amylin deposition in the brain: A second amyloid in Alzheimer disease?
Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F.. Annals of neurology, 2013-07-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective Hyperamylinemia, a common pancreatic disorder in obese and insulin-resistant patients, is known to cause amylin oligomerization and cytotoxicity in pancreatic islets, leading to β-cell mass depletion and development of type 2 diabetes. Recent data has revealed that hyperamylinemia also affects the vascular system, heart, and kidneys. We therefore hypothesized that oligomerized amylin might accumulate in the cerebrovascular system and brain parenchyma of diabetic patients. Methods Amylin accumulation in the brain of diabetic patients with vascular dementia or Alzheimer disease (AD), nondiabetic patients with AD, and age-matched healthy controls was assessed by quantitative real time polymerase chain reaction, immunohistochemistry, Western blot, and enzyme-linked immunosorbent assay. Results Amylin oligomers and plaques were identified in the temporal lobe gray matter from diabetic patients, but not controls. In addition, extensive amylin deposition was found in blood vessels and perivascular spaces. Intriguingly, amylin deposition was also detected in blood vessels and brain parenchyma of patients with late onset AD without clinically apparent diabetes. Mixed amylin and amyloid β (Aβ) deposits were occasionally observed. However, amylin accumulation leads to amyloid formation independent of Aβ deposition. Tissues infiltrated by amylin showed increased interstitial space, vacuolation, spongiform change, and capillaries bent at amylin accumulation sites. Unlike the pancreas, there was no evidence of amylin synthesis in the brain. Interpretation Metabolic disorders and aging promote accumulation of amylin amyloid in the cerebrovascular system and gray matter, altering microvasculature and tissue structure. Amylin amyloid formation in the wall of cerebral blood vessels may also induce failure of elimination of Aβ from the brain, thus contributing to the etiology of AD.
What this study adds
Evidence grade: Low
This study found amylin oligomers and plaques in brain tissue of diabetic patients and also amylin deposition in blood vessels and brain tissue of some late-onset Alzheimer's patients without apparent diabetes. It is a tissue-based finding about a possible second amyloid, not evidence that any treatment cures or prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jackson, K., Barisone, G. A., Diaz, E., Jin, L. W., DeCarli, C., & Despa, F. (2013). Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of neurology. https://doi.org/10.1002/ana.23956
Vancouver
Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of neurology. 2013. doi:10.1002/ana.23956. PMID: 23794448.
BibTeX
@article{jackson2013-23794448,
author = {Jackson, K. and Barisone, G. A. and Diaz, E. and Jin, L. W. and DeCarli, C. and Despa, F.},
title = {{Amylin deposition in the brain: A second amyloid in Alzheimer disease?}},
journal = {Annals of neurology},
year = {2013},
doi = {10.1002/ana.23956},
pmid = {23794448},
url = {https://doi.org/10.1002/ana.23956}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Recent data has revealed that hyperamylinemia also affects the vascular system, heart, and kidneys.
- Results Amylin oligomers and plaques were identified in the temporal lobe gray matter from diabetic patients, but not controls.
Why it matters
This study found amylin oligomers and plaques in brain tissue of diabetic patients and also amylin deposition in blood vessels and brain tissue of some late-onset Alzheimer's patients without apparent diabetes. It is a tissue-based finding about a possible second amyloid, not evidence that any treatment cures or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 341 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.7 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 4 / 6 | Cited 15.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 3 / 4 | Cited 59 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Florin Despa: h-index 26 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of California, Davis: institution h-index 1,257 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23794448) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Risk factors from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.